Sign in
Not yet recruitingPhase 3

A Phase 3 Trial of DR10624 Versus Placebo in Patients With Severe Hypertriglyceridemia

Key facts

Who runs it
Zhejiang Doer Biologics Co., Ltd.
Where
China2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
Phase
Phase 3
People taking part
378 people, planned
Started
Aug 2026
Expected to end
Oct 2030
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • DR10624 Subcutaneous Injection
  • Icosapent Ethyl Oral Capsule
  • Matching Placebo Subcutaneous Injection
Record updated
6 July 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Age ≥18 years, male or female; BMI 19.0-45.0 kg/m², body weight ≥50 kg at screening
  • Fasting triglyceride (TG) range 5.65-22.60 mmol/L: single screening lab result meets range, plus average of two separate fasting TG tests (interval >1 week) within same range prior to randomization
  • Stable lipid-lowering medications per local guidelines if on statin, cholesterol absorption inhibitor or PCSK9 inhibitor (minimum stable dose duration as required by drug class)
  • Females of childbearing potential agree effective contraception from ICF signing to 2 months post last dose; male participants agree contraception and no sperm donation for 3 months post last dose
  • Able to understand study procedures, maintain consistent lifestyle and follow all protocol-specified requirements, and provide written informed consent

Who cannot take part

  • Prior GLP-1/GCGR/FGF21 agonists or other investigational drugs within 3 months
  • Confirmed hereditary lipid disorders (Fredrickson Type 1/3, Apo C-II deficiency)
  • Severe chronic liver, renal or advanced cardiac disease
  • Uncontrolled diabetes or hypertension with severe complications
  • Pancreatitis history or symptomatic gallbladder disease
  • Recent major cardiovascular, bone or thyroid disorders
  • Severe psychiatric illness or substance abuse history
  • Abnormal screening lab parameters related to liver, pancreas, kidney or viral infection
  • Pregnant, breastfeeding or hypersensitivity to study treatments
  • Significant weight loss or planned weight reduction during study
  • Investigator's judgment of unsuitability for participation

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 trial for adults with severe hypertriglyceridemia whose lipid levels remain uncontrolled under standard Icosapent Ethyl background treatment plus lifestyle management. Eligible participants complete a screening run-in period, then randomize equally to three treatment groups: two active DR10624 subcutaneous injection groups and one placebo group. All subjects maintain fixed oral background lipid therapy throughout long-term double-blind treatment, followed by a short safety follow-up period. The primary objective is to evaluate the triglyceride-lowering effect of DR10624 versus placebo. Secondary assessments include other lipid indicators, liver fat content, overall safety, and anti-drug antibody status. Independent committees monitor interim data and adjudicate key clinical events to ensure participant safety.

The 3 groups in the trial

  • Experimental Group 1: Weekly DR10624 InjectionTreatment being tested

    Treatment: DR10624 Subcutaneous Injection and Icosapent Ethyl Oral Capsule

  • Experimental Group 2: Weekly DR10624 InjectionTreatment being tested

    Treatment: DR10624 Subcutaneous Injection and Icosapent Ethyl Oral Capsule

  • Weekly Matching Placebo InjectionPlacebo, for comparison

    Treatment: Icosapent Ethyl Oral Capsule and Matching Placebo Subcutaneous Injection

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of DR10624 Added to Standard Icosapent Ethyl Therapy in Adults With Severe Hypertriglyceridemia
Record updated
6 July 2026